

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel E.H. Afar et al. Assignee: UroGenesys, Inc.
Serial No.: 09/389,000 Examiner: Not yet assigned
Filed: August 31, 1999 Group Art Unit: 1643
Docket: 129.27USU2
Title: PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED IN CANCER



<p>CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8</p> <p>I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on <u>24 July 2000</u>.</p> <p>By: <u>[Signature]</u> Name: Karen S. Canady</p>
--

#5
CO
8-2400

REVOCATION AND POWER OF ATTORNEY

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please revoke the existing Powers of Attorney, if any, and appoint the following attorneys and/or patent agents to prosecute this application and to transact all business in the U.S. Patent and Trademark Office in connection therewith:

George H. Gates	Registration No. 33,500
Victor G. Cooper	Registration No. 39,641
Karen S. Canady	Registration No. 39,927
Anthony J. Orlor	Registration No. 41,232
William J. Wood	Registration No. 42,236
Jason S. Feldmar	Registration No. 39,187

Please direct all correspondence in this application to Karen S. Canady at:

Gates & Cooper
Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, California 90045
Telephone: (310) 641-8797

A Certificate under 37 C.F.R. 3.73(b) is attached.

Respectfully submitted,
UroGenesys, Inc.

Dated: 7/11/00

By: Aya Jakobovits
Aya Jakobovits, Ph.D.
Vice President, Research
Chief Scientific Officer
UroGenesys, Inc.
1701 Colorado Avenue
Santa Monica, CA 90404

RECEIVED

JUL 28 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel E.H. Afar et al. Examiner: Not yet assigned
Serial No.: 09/389,000 Group Art Unit: 1643
Filed: August 31, 1999 Docket: 129.27USU2
Title: PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED IN CANCER

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

UROGENESYS, INC., a corporation organized and existing under the laws of the State of California, having a place of business at 1701 Colorado Avenue, Santa Monica, California 90404, certifies that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of:

An assignment from the inventor(s), Daniel E. H. Afar, Rene S. Hubert, and Arthur B. Raitano to UroGenesys, Inc., of the patent application identified above. A copy of the Assignment is attached.

UroGenesys, Inc. owns 100% interest in the above-identified patent application.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, as the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 7/11/00

By: Aya Jakobovits
Name: Aya Jakobovits, Ph.D.
Title: Vice President, Research
Chief Scientific Officer

ASSIGNMENT

WHEREAS, Daniel E.H. Afar, Rene S. Hubert, and Arthur B. Raitano (hereinafter "Assignor(s)"), made certain new and useful inventions and improvements for which was filed an application for Letters Patent of the United States on August 31, 1999, having Serial No. 09/389,000, which application is entitled PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED IN CANCER.

AND WHEREAS, UroGenesys, Inc., a corporation organized and existing under and by virtue of the laws of the State of California, and having an office and place of business at 1701 Colorado Avenue, Santa Monica, California 90404 (hereinafter "Assignee") is desirous of acquiring the entire right, title and interest in and to said inventions, improvements and application and in and to the Letters Patent to be obtained therefor;

NOW THEREFORE, to all whom it may concern, be it known that for and in consideration of the sum of One Dollar and other good and valuable considerations, the receipt and sufficiency whereof is hereby acknowledged, Assignor(s) have sold, assigned, and transferred, and by these presents do sell, assign and transfer unto said Assignee, its successors or assigns, the entire right, title and interest for all countries in and to all inventions and improvements disclosed in the aforesaid application, and in and to the application, all divisions, continuations, or renewals thereof, all Letters Patent which may be granted therefrom, and all reissues or extensions of such patents, and in and to any and all applications which have been or shall be filed in any foreign countries for Letters Patent on the inventions and improvements, including an assignment of all rights under the provisions of the International Convention, and all Letters Patent of foreign countries which may be granted therefrom; and do hereby authorize and request the Commissioner of Patents and Trademarks to issue any and all United States Letters Patent for the aforesaid inventions and improvements to the Assignee as the assignee of the entire right, title and interest in and to the same, for the use of the Assignee, its successors and assigns.

AND, for the consideration aforesaid, Assignor(s) do hereby agree that they and their executors and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said Assignee, its successors and representatives all facts known to Assignor(s) relating to said improvements and the history thereof and will testify in all legal


proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said Assignee, its successors or assigns the entire right, title and interest in and to the improvements, inventions, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby sold, assigned and conveyed, or intended so to be.

AND, furthermore Assignor(s) covenant and agree with said Assignee, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by Assignor(s) and that full right to convey the same as herein expressed is possessed by Assignor(s).


Date: 7/17/00

Signature: 
Name: Daniel E.H. Afar

Date: 7/17/00

Signature: 
Name: Rene S. Hubert

Date: 7-17-00

Signature: 
Name: Arthur B. Raitano



1643

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Daniel E.H. Afar et al. Examiner: Not yet assigned
Serial No.: 09/389,000 Group Art Unit: 1643
Filed: August 31, 1999 Docket: 129.27USU2
Title: PHELIX: A TESTIS-SPECIFIC PROTEIN EXPRESSED IN CANCER

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on July 24, 2000.

By: 

Name: Karen S. Canady

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing under 37 CFR 1.8.
- ☒ Revocation and Power of Attorney including Certificate Under 3.73(b) and copy of Assignment
- ☒ Return postcard.

RECEIVED

JUL 28 2000

TECH CENTER 1000 2000

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers, if appropriate.

Please charge any additional fees or credit any overpayment to Deposit Account No. 50-0494 of Gates & Cooper. A duplicate of this paper is enclosed.

Customer Number 22462.

GATES & COOPER
Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, CA 90045
(310) 641-8797

By: 

Name: Karen S. Canady

Reg. No.: 39,927

KSC/sjm

(PTO TRANSMITTAL - GENERAL)